

RxAir360 Inc.

Unaudited Financial Statements

For the Year Ended December 31, 2024

Balance Sheet

Assets	
Total Assets	\$3,027,177.68
Liabilities	
Total Liabilities	\$2,535,825.00

Stockholders' Equity: \$491,352.68

Total Liabilities & Equity: \$3,027,177.68

Statement of Operations

Revenue: \$13,560.00

Cost of Goods Sold: \$0.00

Gross Profit: \$13,560.00

Operating Expenses: \$1,565,985.00

Operating Loss: (\$1,552,425.00)

Other Income (Expense), net: (\$524.42)

Net Loss: (\$1,552,949.42)

Statement of Cash Flows

Net Cash (Used in) Operating Activities: (\$1,552,949.42)

Net Cash (Used in) Investing Activities: (\$1,932.94)

Net Cash Provided by Financing Activities: \$1,501,715.84

Net Change in Cash: (\$53,166.52)

Cash, Beginning of Period: \$78,411.26

Cash, End of Period: \$25,244.74

Statement of Changes in Stockholders' Equity

Common Stock	APIC	Accumulated Deficit	Total Equity
\$0.00	(included in equity total)	(\$1,552,949.42)	\$491,352.68

Notes to Financial Statements

1. Organization and Nature of Operations

RxAir360 Inc. is a Delaware C-Corporation engaged in the development and commercialization of medical devices. The financial statements presented are unaudited and prepared in accordance with U.S. GAAP for interim reporting.

2. Basis of Presentation

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). These financial statements are unaudited and reflect all adjustments, consisting of normal recurring adjustments, necessary for fair presentation.

3. Significant Accounting Policies

- Revenue Recognition: The Company recognizes revenue in accordance with ASC 606.
- Stock-Based Compensation: Accounted for under ASC 718.
- SAFE Notes and Equity: Pre-February 20, 2025 investments are classified as equity; subsequent investments are classified as SAFE Notes payable.
- Intangible Assets: Patents are capitalized and amortized over their useful life.

4. Related Party Transactions

The Company has a patent assignment agreement with Stanley Thaw totaling \$3,000,000, of which \$500,000 has been paid to date.

5. Commitments and Contingencies

Management continues to negotiate payment schedules with key vendors including Electroimpact for manufacturing support.

6. Subsequent Events

Management has evaluated subsequent events through July 2, 2025, the date these financials were issued.

Management Certification

To the best of my knowledge, the information contained herein is true and correct as of the date indicated below.

Diallo M. Watts, Sr.

Diallo M. Watts, Sr.

Founder & CEO, RxAir360 Inc.

Date: July 2, 2025